Semaglutide, under the brand name Wegovy, is Food and Drug Administration-approved for chronic weight management in adults with a body mass index (BMI) of 30 or higher who have at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol
"I was just constantly in a state of being overwhelmed," says Kent
Patients were followed up for up to 2 years to assess discontinuation and for 2 additional years to assess reinitiation
Notably, IFF research shows many UK GLP-1 consumers appear to be assembling a holistic toolkit balancing protein with hydration, digestive support and nutrient density
Theres only one phase one trial thats registered right now, and its been registered since 2016, and nothing has been updated on that registration, so that tells you something as well